Investigated for treating COVID-19.
Tocilizumab-bavi (Tofidence) is biosimilar to Tocilizumab (Actemra).
Approved 09/29/2023
Tocilizumab-Aazg (Tyenne) is biosimilar to Tocilizumab (Actemra).
Approved 03/05/2024
- TRADE NAMES: Actemra (Roche); Atlizumab; RoActemra (Roche)
- INDICATIONS: Rheumatoid arthritis, juvenile idiopathic arthritis, Castleman’s disease
- CLASS: Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Covid-19 putative drug, Disease-modifying antirheumatic drug (DMARD), Interleukin-6 inhibitor / anti-interleukin 6 receptor monoclonal antibody, Monoclonal antibody
- HALF-LIFE: 8–14 days
- FDA APPROVAL DATE: 01/08/2010
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Dolasetron, Efavirenz, Fesoterodine, Fingolimod, Infliximab, Lurasidone, Paricalcitol, Pazopanib, Typhoid Vaccine, Yellow Fever Vaccine - PREGNANCY: Based on animal data, may cause fetal harm
RISK OF SERIOUS INFECTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tocilizumab in the treatment of juvenile idiopathic arthritis in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/29/2024
